Loading chat...
IN SB0327
Bill
Status
1/9/2017
Primary Sponsor
Brandt Hershman
Click for details
AI Summary
-
Defines "cannabidiol" as the chemical compound 2-(6-isopropenyl-3-methyl-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol for purposes of Indiana Code IC 35-48-4-11.
-
Provides an affirmative defense to marijuana possession charges if the substance contains cannabidiol and meets all specified requirements.
-
Requires cannabidiol products to be pharmaceutical products from FDA-approved wholesale drug distributors or part of clinical trials by governmental entities or accredited colleges/universities.
-
Mandates cannabidiol containers be labeled with origin, volume, and concentration of active ingredient, and contain zero delta-9-tetrahydrocannabinol (THC).
-
Limits the defense to persons with a physician's written diagnosis of Dravet syndrome or Lennox-Gastaut syndrome, or parents/guardians/caretakers of children with those diagnoses.
Legislative Description
Medicinal use of cannabidiol. Defines "cannabidiol", and provides an affirmative defense to possession of cannabidiol if the person or the person's child has been diagnosed with certain medical conditions, the cannabidiol contains no THC, and other specified conditions are met.
Last Action
First reading: referred to Committee on Corrections and Criminal Law
1/9/2017